Metabolic dysfunction-associated steatotic liver disease (MASLD), also known as fatty liver disease, is a chronic liver condition that affects nearly 1 in 3 people worldwide. It is closely linked to obesity, type 2 diabetes, and metabolic syndrome. Unchecked, it can progress to a more severe form of disease called Metabolic Dysfunction-Associated Steatohepatitis (MASH).

Prognosticating the risk of disease progression in MASLD and MASH has traditionally involved liver biopsy, a process that involves removing a tissue sample with a hollow needle and then examining the sample under a microscope to diagnose and stage disease. However, biopsy has many limitations. Additionally, drug development for MASLD and MASH has proceeded slowly in part due to a reliance on liver biopsy to determine drug efficacy.

Recently, increasing evidence is suggesting that non-invasive options, for example, imaging examinations along with blood tests that assess likelihood of disease progression such as the Enhanced Liver Fibrosis (ELF) Test, may effectively reduce the need for the more invasive alternative. Key experts in MASLD and MASH share their perspectives about how clinical evidence supports a shift in the way patients with MASLD and MASH could be evaluated in clinical practice and in research.

Host Matt Gee, Director of Collaborations and External Engagement at Siemens Healthineers, is joined by Prof. William Rosenberg, Deputy Director of the Institute for Liver and Digestive Health at University College London as well as Dr. Veronica Miller, Director of the Forum for Collaborative Research at the University of California, Berkeley School of Public Health; Dr. Arun Sanyal, Professor of Medicine, Physiology, and Molecular Pathology in the Division of Gastroenterology at Virginia Commonwealth University; and Dr. Michelle Long, International Medical Vice President of Metabolic Dysfunction-Associated Steatohepatitis at Novo Nordisk and Associate Professor in the Section of Gastroenterology and Hepatology at Boston University.

What you’ll learn in this episode:

Liver biopsy creates several obstacles for patients and has limitations
Drug development faces challenges by the reliance on biopsy as a measure of treatment effectiveness
Non-invasive tools may be suitable alternatives to liver biopsy both in clinical practice and in drug development

Connect with Matt Gee

LinkedIn

Connect with Veronica Miller

LinkedIn

Connect with William Rosenberg

LinkedIn

Connect with Michelle Long

LinkedIn

Connect with Arun Sanyal

VCU.edu

Hosted on Acast. See acast.com/privacy for more information.

Open to Life: Emerson College, 16-21 June 2025, part 1

James Low - Dzogchen and Buddhist Teachings

Relating to Thoughts: Loving the Vanishing

The AI-powered Podcast Player